Financial Performance - Total revenue for the fiscal year ending March 31, 2024, was approximately HKD 181,092,000, an increase of about 4.25% compared to HKD 173,702,000 in the previous year[2]. - Gross profit decreased to approximately HKD 54,740,000, down about 3.86% from HKD 56,936,000 in the previous year[2]. - Operating loss for the year was approximately HKD 39,438,000, compared to an operating profit of HKD 4,473,000 in the previous year[2]. - Loss attributable to owners of the company was approximately HKD 39,977,000, compared to a profit of HKD 1,820,000 in the previous year[2]. - Basic and diluted loss per share was approximately HKD 7.14, compared to earnings of HKD 0.32 per share in the previous year[4]. - The company reported a net loss of HKD 40,295,000 for the year, compared to a profit of HKD 1,938,000 in the previous year[4]. - The company experienced an operating loss of HKD 39,438,000 for the fiscal year ending March 31, 2024, compared to an operating loss of HKD 30,890,000 in the previous year[19][21]. - The company recorded a net expected credit loss provision of HKD 4,595,000, compared to a reversal of HKD 7,499,000 in the previous year[31]. - The company recorded a loss attributable to shareholders of approximately HKD 39,977,000 for the year, compared to a profit of HKD 1,820,000 in 2023[58]. Revenue Segments - The blood dialysis service segment generated revenue of HKD 121,424,000, while the pharmaceutical wholesale and distribution segment generated revenue of HKD 52,278,000 for the fiscal year ending March 31, 2024[21]. - Revenue from blood dialysis treatment and consulting services increased by 6.5% to HKD 129,556,000 from HKD 121,424,000[32]. - Revenue from the pharmaceutical wholesale and distribution business was approximately HKD 51,536,000, a decrease of about 1.42% from HKD 52,278,000 in 2023[49]. - Revenue from the hemodialysis treatment and consulting services business was approximately HKD 129,556,000, an increase of 6.7% from HKD 121,424,000 in 2023[50]. Assets and Liabilities - Total assets as of March 31, 2024, amounted to HKD 117,101,000, a decrease from HKD 173,448,000 as of March 31, 2023[23]. - Total liabilities as of March 31, 2024, were HKD 41,906,000, down from HKD 53,221,000 in the previous year[23]. - Non-current assets decreased to HKD 58,709,000 from HKD 96,579,000 in the previous year[6]. - Total equity attributable to owners of the company decreased to HKD 73,488,000 from HKD 118,197,000 in the previous year[7]. Cash and Dividends - Total cash and cash equivalents as of March 31, 2024, were approximately HKD 18,228,000, an increase from HKD 9,876,000 in the previous year[2]. - The company did not recommend a final dividend for the year ending March 31, 2024, consistent with the previous year[2]. - The company did not declare any dividends for the year ended March 31, 2024, consistent with 2023[37]. Corporate Governance - The company is committed to maintaining high standards of corporate governance and compliance with the Hong Kong Stock Exchange's listing rules[79]. - The company aims to enhance long-term value for shareholders and maintain high standards of corporate governance, with ongoing reviews of board diversity policies[93][100]. - The board consists of one executive director and three non-executive directors, ensuring a balance of experience and skills[102]. - The audit committee held three meetings during the fiscal year ending March 31, 2024, and reviewed the group's financial performance, ensuring compliance with applicable accounting standards and adequate disclosures[88]. - The remuneration committee also held three meetings in the fiscal year, focusing on the compensation policies for all directors and senior management, ensuring transparency and fairness in remuneration practices[91]. - The nomination and corporate governance committee conducted two meetings during the fiscal year, reviewing the board's structure and diversity, and plans to nominate at least one female member by the end of 2024[95][94]. Future Outlook - The company has applied new accounting policies for lease transactions occurring on or after April 1, 2022, which may impact future financial statements[17][16]. - The company faced a goodwill impairment loss of approximately HKD 22,310,000, impacting future profitability expectations[60]. - The company plans to fill the vacancy of independent non-executive director within three months following the resignation of a director on April 30, 2024[82]. - The company is committed to creating long-term value for shareholders through continuous efforts and support from stakeholders[100].
万嘉集团(00401) - 2024 - 年度业绩